

INDEX

- Absorption, 1, 3–13, 44–48, 50–51, 53–56, 58–63, 65, 98, 100, 102–103, 105–107, 111–117, 119–124, 126–127, 145, 152, 155, 164, 181–183, 186–187, 192–193, 196–197, 208, 226, 230, 242, 244–247, 251, 256, 264, 270–273, 277, 285, 292–294
- Absorption lag, 94, 208
- Absorption number, 111, 112, 116
- Absorption profile, 1–11, 12–13, 20, 59, 94, 96, 100, 105, 121, 122, 125, 243, 245–247, 256, 277
- Absorption window, 105, 116, 120–121, 123–124, 126–127, 155, 200
- Accelerated stability, 221–222, 224
- ADAPT II, 53, 200, 208
- AIC: *see* Akaike Information Criteria
- Akaike Information Criteria, 34, 48, 200, 209
- Animal absorption/permeability models, 182–3
- Artificial neural networks (ANN), 149–158, 163, 225–240
- backpropagation with, 150–152, 154, 156, 226, 229–230, 235, 237–238
 - feed forward with, 150, 152–153, 156–157, 228, 230, 234–235
 - fitness function, 229
 - jump connection, 230, 235
 - mapping network, 150, 152, 156,–7
 - memorization, 152–153, 229, 243, 236
 - pattern files, 229–230, 232, 234, 236
 - processing elements, 150
 - recurrent, 150, 152, 156, 228, 230
- AUC, 17, 22, 24–25, 27–28, 31, 58, 61, 65, 94, 96, 98–100, 102–103, 105, 108, 121, 140, 145, 180, 218–219, 224, 267–268, 272–273, 276, 279, 281, 284–285, 287–288, 290–291
- Bioavailability, 270, 274–276, 279–280, 282–283, 286
- Bioequivalence, 269–270, 274, 282–283
- Biopharmaceutical classification, 114, 294
- Biorelevant dissolution, 2–4, 9, 11, 13
- Biowaivers, 267, 281–286
- “By Chance” model, 91
- Caco-2, 182–186, 188
- Carbamazepine, 31, 33–34, 37, 41
- Chemical substitution, 144, 145
- C_{max}, 17, 22, 24–25, 27–28, 31, 58, 61, 65, 94, 96, 98–100, 102–103, 105, 108, 121, 130, 140, 145, 180, 218–219, 224, 252, 267–268, 272–273, 276, 279, 281, 284–285, 287–288, 290–291
- Coincidence hypothesis, 168, 171
- Complementary log-log function, 75, 77
- Compound symmetry, 70, 86
- Confidence region (CR), 34, 39, 41
- components of, 40
 - ellipse of, 39, 40
- Confocal microscopy, 129, 258
- Convolution, 3, 4, 13, 44, 48, 53–65, 149, 155, 164, 226, 268, 270, 271, 276, 287, 292
- Covariance, 33–34, 36–39, 47–48, 70, 85–86, 167–168, 175
- Critical formulation components: *see* critical manufacturing variables
- Critical formulation variables: *see* Critical manufacturing variables
- Critical manufacturing parameters: *see* Critical manufacturing variables
- Critical manufacturing variables, 3, 9, 11, 14, 137–148, 157, 250, 253, 290
- Cross-validation, 89–91, 270, 281
- Deconvolution, 3, 4, 6, 11, 13, 31, 43, 54–55, 65, 67, 79, 97, 100, 105, 135, 145, 149, 153–155, 173–174, 200, 208, 270–271, 275, 292
- Diluent grade: *see* Formulation variables, diluent grade
- Dissolution factor, 20
- Dissolution, *in vitro*, 1, 5–9, 13–14, 19, 22, 25–27, 31–42, 69, 73, 78–79, 89–91, 94, 96, 98–100, 102–108, 110, 112, 114, 120–121, 123, 127, 139, 145, 192, 196–197, 199–200, 208, 225, 230, 234, 270–272, 274–287, 290–294
- apparatus (USP I–IV), 3–5, 9, 13–14, 18–19, 93–94, 96, 217–220, 222, 248, 277, 279
 - assay for, 17–30

- Dissolution, *in vitro* (cont.)
 conditions for, 2, 19, 24
 data from, 9, 18, 20, 67–69, 72, 78, 100, 205, 230, 232, 262
 discriminating methods for, 20, 96–97, 105, 137, 139, 143, 146, 160, 166, 217–221, 223–224, 265, 278, 290
 extent of, 25, 26
 methods for, 28, 94, 96–97, 100, 102–103, 105–106, 108, 122, 137, 139, 143, 145, 217, 221, 224, 234, 244, 246, 290
 model for, 112, 113
 optimization of, 17, 29, 290
 specifications for, 2, 9–14, 53, 110, 114, 159–167, 174, 199, 225, 262, 266–267, 269, 274–276, 281–282, 284–287, 290–291
 surrogate for bioequivalence, 2–3, 14, 160, 166, 199, 247–248, 261–262, 266, 274, 279, 282, 286
 test, 2, 9, 17–20, 22, 24–28, 95, 110, 139, 144, 149, 152, 199, 217, 261, 263, 266, 272, 274, 277–278, 282–283, 285–6
 time, 113, 230
 variables of, 19, 25, 28, 29
 effect of agitation, 3, 19, 25–26, 29, 94, 108, 218, 243, 277, 279, 283, 290, 293
 effect of medium, 3, 19–20, 22, 26, 93, 114, 119, 126–127
 effect of pH, 3, 9, 18–27, 60, 93–95, 116, 118–120, 127, 160, 243–244, 246–247, 264, 277, 279, 283, 290, 293
 effect of phosphate buffer, 93–94, 96, 222
- Dissolution, *in vivo*, 3–4, 7, 19, 69, 73, 78, 79
 Dissolution number, 112–113, 116, 127
 Dissolution profiles, 3–5, 7–9, 20, 22, 29, 31–42, 78, 89, 94–95, 100, 105, 108, 121, 140, 142–144, 149, 156, 167–172, 174, 192, 200, 224, 226, 228–230, 232, 274, 277, 279, 281–287
 comparison of, 31–42,
 approaches to, 33
 model dependent approach to, 40
 model independent approach to, 34
- Dissolution rate, 1, 3, 30, 119–120, 123, 173–180, 192
 Distribution function, 61, 72–73
 Dosage form, 1–4, 7, 9, 13, 17–19, 30, 79, 111, 113–116, 120, 121, 124, 127, 191, 196–197, 253, 259, 269, 271–273, 276–278, 287–288
 controlled release (CR): *see* Dosage form, extended release
 extended release (ER), 31, 53, 111, 113, 115, 118, 120–127, 129, 137, 159, 167, 173–174, 182, 208, 217, 220, 241, 243, 246, 248–249, 255, 256, 258, 261, 271, 274, 284, 286, 289
 immediate release (IR), 19, 22–25, 31, 33, 53–56, 59–60, 62–63, 65, 111–112, 114–115, 120, 127, 164, 173, 200, 208, 217, 228, 241, 250, 292
 modified release (MR): *see* Dosage form, extended release
- Dose number, 18, 22, 30, 111–114, 116, 119–121
 Drug release mechanism, 19, 20
 Drug stability, 18
- Emax model, 7
 Experimental design, 19, 88, 138, 144, 250
- F₂ Equation, 8–9, 33, 168–169, 171, 285
- Formulation variables
 diluent grade as a, 138, 140, 143
 matrix tablet as a, 93, 217, 221
 methocel as a, 93
 multiparticulate formulation as a, 93, 113, 121, 124
 particle size as a, 137–138, 140–143, 145–146, 181, 191
 physiochemical properties as a, 1, 3, 31, 93, 108, 117, 127, 181, 184, 191, 243–245, 247
 polymer as a, 137, 219–220, 224, 251, 294
 surfactant as a, 3, 9, 19, 25–28
 tablet hardness as a, 138, 140, 143–145, 220
- Gastric emptying, 46, 95, 114
 Gastrointestinal tract (GIT), 58, 60, 108, 111, 117–118, 120–123, 126–127, 265, 289
 Generalised linear mixed effects model (GLMM), 78–79, 86, 98, 103, 107, 109
 Gompertz model, 7, 205–206, 208, 210–211
 Goodness of fit, 88, 89, 205, 208–210
- Hazard function, 73, 75
 Higuichi model, 113, 200, 205
 Hixson–Crowell model, 200, 205–206, 215
 Hotelling's T², 38, 70, 72, 85, 168–169, 171
 Hydrophilic matrix, 19, 129, 137–139, 144–145, 152, 217, 220–224,
 Hydrophilic polymer matrix: *see* Hydrophilic matrix
 Hydroxypropyl methylcellulose (HPMC), 130, 137–138, 140, 143–145, 217–220
 Hypothesis of coincidence: *see* Coincidence hypothesis
- Identity model, 73–75, 78, 86
 Impulse response, 56–57, 60, 62–63, 97, 155, 208, 226, 292
 Inter-individual variability: *see* Intersubject variability
 Intersubject variability, 46, 52, 161–164, 166, 207–208, 210, 214–215
In vitro release, 44–45, 53–57, 59–63, 65, 149, 155, 164, 272, 279–280
In vivo input, 1, 54, 270, 276, 278
In vivo performance, 1–2, 4, 8–9, 160–161, 164, 261, 278–280, 282, 286
 Ionic strength, 19–21, 25–26, 94, 108, 220, 290
 IVIVC
 level A, 3–7, 32, 54–65, 67–70, 72, 85, 86, 88, 98, 102–103, 107, 110, 126–127, 161, 174, 192, 199–206, 207–215, 243, 245, 248, 250–251, 256, 258, 262, 271, 274–281, 287, 292–293
 level B, 32, 174, 262, 271, 274, 276–277, 282

- IVIVC (*cont.*)
level C, 32, 98, 100, 102, 104, 110, 174, 245, 262, 271, 274, 276–277, 282
rank order, 22, 25–26, 96, 105, 197, 246, 262
IVIVR: *see* IVIVC
- Linear mixed effects model, 86, 98, 103, 107, 109–110, 168–171
Linear model, 67, 69, 72–73, 103, 155, 200, 210, 214–215
Link function, 78
Liquid ingress, 131–133
Logistic model, 34–35, 200, 205–206, 215, 230, 237
Logit function, 75, 78
Loo–Riegelman, 4, 55; *see also* Deconvolution
- Mahalanobis distance, 37–38, 168
Mahalanobis distance vector matrix, 41
MANOVA: *see* Multivariate analysis of variance
Mapping, 9, 290–291
Mathematical models, 17, 33–34, 44–46, 88, 103, 199, 270–271, 278, 287
Matrix tablet: *see* Formulation variables, matrix tablet
Maximum likelihood, 48, 79, 209–210, 215
Methocel: *see* Formulation variables, methocel
Mitcherlich model, 200, 205, 208, 210, 213
Mixed effects model, 70, 72, 85, 86, 207, 210, 214–215
Multiparticulate formulation: *see* Formulation variables, multiparticulate formulation
Multivariate analysis of variance, 70, 168–169
- Naive model, 90–91, 207, 281
Narrow therapeutic index, 89
Neural networks: *see* Artificial neural networks
Nonlinear mixed effects model, 9, 48, 176–177, 207–215
Nonlinear models, 7, 55, 58–59, 67, 70, 72–77, 86, 155, 157, 196, 199–206, 207–15
Nonlinear presystemic elimination: *see* Saturable presystemic elimination
NONMEM: *see* Nonlinear mixed effects model
Non-parametric, 43–53
- Odds function, 73
Operating characteristic (OC), 85, 169, 171
curve, 70, 85, 169, 171
- Particle size: *see* Formulation variables, particle size
PCDCON, 4, 97, 200, 208; *see also* Deconvolution
Permeability, 60, 100, 105–106, 110–112, 115–118, 120, 124–127, 181–190, 197, 243–245, 247, 289
Permeability regional, 181–190
Physicochemical properties: *see* Formulation variables, physicochemical properties
Plasma concentration, 54–58, 60, 62–64, 160–163, 166, 208, 230, 238, 245, 268
Polymer: *see* Formulation variables, polymer
- Polynomial model, 7, 229
Pooled standard deviation, 35–36
Power, 70, 85–86, 171
Predictability, 2, 54–56, 58, 60–65, 87–92, 108, 110, 145, 147, 149, 154–155, 157, 160–161, 163–164, 166, 174, 199, 206, 210, 225, 230, 234–235, 238, 252–254, 256, 258, 261, 267, 269, 275, 278–283, 286, 292–293
external predictability, 89–90, 279–280, 283–285
internal predictability, 89–91, 278–281
prediction error, 89–91
Product development, 105, 110, 241–260
Proportional hazards model, 75–78, 80–81, 83–84, 86
Proportional odds model, 73–74, 78–79, 80, 82–83, 86
Proportional reverse hazards model, 76–78, 81–82, 84–86
Prospective IVIVR, 97, 241–260
- Quality control, 1–2, 96, 105, 159, 199, 266
- Random vector, 70, 168
Ranitidine, 191–197
Rank order: *see* IVIVC, rank order
Regression analysis, 5–7, 19–21, 69, 71, 85–86, 104–105, 199
Resampling, 91
Rescigno index, 8, 13
Residence time, 32, 112–113, 116, 124
Response surface methodology, 19, 26–28
Retrospective IVIVR, 241–260
Reverse hazard function, 73, 76
- Saturable first pass effect, 58
Saturable presystemic elimination, 58, 60–62
Semi-parametric, 46, 51
Sigmoid model, 103, 151, 200, 202, 205–206, 208–214
Similarity Region (SR): *see* Univariate similarity region
Simulated data, 34, 47–52, 70–72, 176–179, 226
Simulation experiment, 167, 169, 171
Site dependence, 133
Solubility, 3, 18–19, 22, 25, 30–31, 94, 113–114, 116, 118–120, 122, 126–127, 181, 244, 248
Solubility, sink conditions, 3, 18, 22, 108, 127
Standard two stage approach, 48, 199–206, 207–215
Statistical methods, 67
Statistical model, 77–78
STELLA II, 4
SUPAC (scale-up and post approval changes), 2, 33, 112, 116, 168, 171, 197, 241
Superimposition, 5, 36
Surfactant: *see* Formulation variables, surfactant
- Tablet hardness: *see* Formulation variables, tablet hardness
Time scaling, 59, 199, 278, 292
Time shifting, 6

Transit time, 60–61, 122, 273

Type I error, 71, 85, 169, 171

Type II error, 85

Unit impulse response: *see* Impulse response

Univariate similarity region, 34–36, 39, 41

Validation, 3, 13–14, 87–92, 155, 257, 274, 293–294

empirical validity, 88

external validation, 87–88

Validation (*cont.*)

heuristic validity, 88

internal validation, 87–90

pragmatic validity, 88–89

theoretical validity, 88

Wagner–Nelson, 4, 13, 121, 193 ;*see also* Deconvolution

Weibull function, 7, 20, 34–37, 39–40, 200, 202, 205–206, 208–214, 274, 287